kainos loboratories,inc Logo

kainos loboratories,inc

Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.

4556 | T

Overview

Corporate Details

ISIN(s):
JP3205650009
LEI:
Country:
Japan
Address:
文京区本郷二丁目38番18号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kainos Laboratories, Inc., founded in May 1975, is a company engaged in the research, development, manufacturing, and sale of clinical diagnostic products. It specializes in innovative clinical testing reagents, including biochemical and immunochemistry diagnostics, and also handles pharmaceuticals. The company's operations encompass the entire product lifecycle, from R&D to marketing, distribution, and import/export activities. Kainos Laboratories positions itself as a pioneer in its field, focused on creating innovative medical diagnostic tools for the healthcare industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 02:17
Registration Form
確認書
Japanese 8.1 KB
2025-11-06 02:16
Interim Report
半期報告書-第51期(2025/04/01-2026/03/31)
Japanese 157.7 KB
2025-06-20 03:02
Governance Information
内部統制報告書-第50期(2024/04/01-2025/03/31)
Japanese 21.9 KB
2025-06-20 03:00
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 02:59
Annual Report
有価証券報告書-第50期(2024/04/01-2025/03/31)
Japanese 710.6 KB
2025-06-20 02:56
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-11-06 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-06 01:38
Interim Report
半期報告書-第50期(2024/04/01-2025/03/31)
Japanese 160.1 KB
2024-06-21 03:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-21 03:06
Governance Information
内部統制報告書-第49期(2023/04/01-2024/03/31)
Japanese 21.1 KB
2024-06-21 03:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-21 03:02
Annual Report
有価証券報告書-第49期(2023/04/01-2024/03/31)
Japanese 704.8 KB
2024-02-02 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-02 01:38
Quarterly Report
四半期報告書-第49期第3四半期(2023/10/01-2023/12/31)
Japanese 135.5 KB
2023-11-02 02:27
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all kainos loboratories,inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for kainos loboratories,inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for kainos loboratories,inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Whitehawk Therapeutics, Inc. Logo
Develops advanced antibody-drug conjugates (ADCs) for difficult-to-treat cancers.
United States of America
WHWK
WooGeneB&GCO.,Ltd Logo
Manufactures veterinary medicines, vaccines, and supplements for livestock and aquatic animals.
South Korea
018620
X4 Pharmaceuticals, Inc Logo
Developing and commercializing novel therapies for rare diseases of the immune system.
United States of America
XFOR
XBiotech Inc. Logo
Develops therapeutic antibodies from natural human immunity for inflammatory diseases and oncology.
United States of America
XBIT
Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY

Talk to a Data Expert

Have a question? We'll get back to you promptly.